Background: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting
tumour angiogenesis and proliferative signalling. The objective of this study was to assess …

The advent of targeted anticancer therapies over the past few decades has reinvigorated the
field of cancer therapeutics, with the promise of increased cancer cure rates accompanied …

Lung cancer has long been recognized as an extremely heterogeneous disease, since its
development is unique in every patient in terms of clinical characterizations, prognosis …

Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …

Background EGFR mutation status is closely related to the efficacy of EGFR-TKIs in
advanced non-small cell lung cancer (NSCLC). EGFR-TKIs have become the standard first …

Purpose Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are key drugs in
the treatment of non-small cell lung cancer (NSCLC) harboring EGFR activating mutations …

Background Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …

由于每一肺癌患者在临床特征、 预后、 治疗反应和耐受性方面的进展都是独特的，
所以肺癌被认为是异质性疾病。 个体化用药是指运用标志物来预测哪些患者更易获益于某种 …

Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance
due to individual tailoring of the therapeutic options and the use of strategies based on both …

Objective Erlotinib has demonstrated survival benefit in patients with not only
adenocarcinoma but also squamous cell carcinoma. Epidermal growth factor receptor …